Courts

241 - 260 of 738 Results

  • What the Health? From KFF Health News

    The Abortion Pill Goes Back to Court

    Episode 298

    A three-judge appeals court panel heard testimony this week about revoking the FDA’s 22-year-old approval of a key pill used in medication abortion and miscarriage management. The judges all have track records of siding with abortion foes. Meanwhile, as the standoff over raising the federal debt ceiling continues in Washington, a major sticking point is whether to impose work requirements on recipients of Medicaid coverage. Victoria Knight of Axios, Rachel Roubein of The Washington Post, and Sandhya Raman of CQ Roll Call join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.

    Listen Now
  • Lawyer Fees Draw Scrutiny as Camp Lejeune Claims Stack Up

    The Camp Lejeune Justice Act, which became law last year, created a pathway for veterans and their families to pursue damage claims against the government for toxic exposure at the military base. Now, advocates and lawmakers worry high lawyer fees could shortchange those injured.

  • What the Health? From KFF Health News

    Health Programs Are at Risk as Debt Ceiling Cave-In Looms

    Episode 296

    A warning from the Treasury Department that the U.S. could default on its debt as soon as June 1 has galvanized lawmakers to intervene. But there is still no obvious way to reconcile Republican demands to slash federal spending with President Joe Biden’s demand to raise the debt ceiling and save the spending fight for a later date. Meanwhile, efforts to pass abortion bans in conservative states are starting to stall as some Republicans rebel against the most severe bans. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Alice Miranda Ollstein of Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.

    Listen Now
  • What the Health? From KFF Health News

    Will They or Won’t They (Block the Abortion Pill)?

    Episode 294

    The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.

    Listen Now
  • An Arm and a Leg

    A $229,000 Medical Bill Goes to Court

    Season 9, Episode 5

    Lisa French was told her surgery would cost $1,337. But the hospital sent her a bill for $229,000, then sued her. The case went all the way to the Colorado Supreme Court. The court’s ruling could have major implications for determining a “reasonable price” in health care.

    Listen Now
  • What the Health? From KFF Health News

    The Confusing Fate of the Abortion Pill

    Episode 293

    The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.

    Listen Now
  • A photo of mifepristone and misoprostol abortion pills.

    Judge Signals He Could Rule to Halt Sales of Common Abortion Pill

    A U.S. District Court case is being widely followed because the judge’s decision could overturn the FDA’s approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.

  • What the Health? From KFF Health News

    Judging the Abortion Pill

    Episode 289

    Any day now a conservative federal judge in Texas could upend the national abortion debate by requiring the FDA to rescind its approval of mifepristone, a drug approved in the U.S. more than 20 years ago that is now used in more than half of abortions nationwide. Meanwhile, a controversial study on masks gets a clarification, although it may be too late to change the public impression of what it found. Alice Miranda Ollstein of Politico, Jessie Hellmann of CQ Roll Call, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.

    Listen Now